Revvity Inc vs Trip.com Group Ltd — how do they compare? Revvity Inc trades at $152.05 (market cap $17.14B), while Trip.com Group Ltd trades at $38.7 (market cap $24.30B). The key difference: Trip.com Group Ltd is the larger of the two by market cap, and Trip.com Group Ltd pays the higher dividend (0.42%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Trip.com Group Ltd for 79 Days on average.
| RVTY | TCOM | |
|---|---|---|
Market Cap | $17.14B | $24.30B |
Volume | 2,226,396 | 1,885,560 |
Sector | Health | Consumer Cyclical |
52-Week High | $157.36 | $78.96 |
52-Week Low | $82.26 | $37.96 |
Typical Hold Time | 12 Days | 79 Days |
Enterprise Value | $19.46B | $16.46B |
Dividend Yield | 0.18% | 0.42% |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. Operating cash flow improved to $628 million in 2026 from $583 million in 2025.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics pose near-term risks. The company faces margin pressures in China and competitive challenges. With 52% analyst buy ratings and strong institutional interest, the stock offers upside to the $165 high target but requires monitoring of Q3 earnings due November 3.
Trip.com (TCOM) trades at $37.96, down 0.78% on the day, amid a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 36.9% net income margin and trades at a low P/E of 7.36. Recent Q2 2026 earnings beat expectations, yet regulatory pressures and a challenging travel environment create headwinds. Analyst consensus remains strongly bullish with a $56.64 price target, indicating significant upside potential from current levels.
The outlook for TCOM balances strong earnings growth and attractive valuation against regulatory risks and market volatility. Investment opportunity lies in its dominant travel platform and international expansion, but investors face risks from antitrust penalties and competitive pressures. The stock's current discount to analyst targets presents a potential value opportunity if execution remains solid.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →